NCT05597839: An ongoing trial by Dragonfly Therapeutics
This trial is ongoing. It must report results 4 months, 1 week from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05597839 |
|---|---|
| Title | A Phase 1/1b First-In-Human, Multi-Part, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF9001 as a Monotherapy and in Combination Therapies in Patients With Advanced (Unresectable, Recurrent, or Metastatic) Solid Tumors, and Expansion in Selected Indications |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 15, 2022 |
| Completion date | Aug. 15, 2025 |
| Required reporting date | Aug. 15, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |